Dynamic RMST curves for survival analysis in clinical trials
Abstract Background The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the proportional hazards (PH) assumption is often violated such that the commonly used log-rank test can be very underpowered. In t...
Main Authors: | Jason J. Z. Liao, G. Frank Liu, Wen-Chi Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12874-020-01098-5 |
Similar Items
-
RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer
by: Berta Luzón-Toro, et al.
Published: (2021-01-01) -
Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions
by: Brennan C. Kahan, et al.
Published: (2020-09-01) -
On comparison of net survival curves
by: Klemen Pavlič, et al.
Published: (2017-05-01) -
Understanding estimands
by: Nithya Jaideep Gogtay, et al.
Published: (2021-01-01) -
Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
by: Shuang Zhang, et al.
Published: (2021-07-01)